Sign In
Buy JNJ
$241.00
+1.92 (+0.80%)
At Close: Jun 24, 2026
Johnson & Johnson beats on earnings and hikes outlook as medtech, pharmaceutical sales surge
06:25am, Tuesday, 17'th Oct 2023
It marks J&J's first quarterly results since the company completed the separation from its consumer health spinoff Kenvue in August.
J&J raises annual profit forecast on anti-inflammatory drug demand
06:22am, Tuesday, 17'th Oct 2023
Johnson & Johnson on Tuesday raised its 2023 profit forecast, helped by resilient demand for its anti-inflammatory drug Stelara and recorded a $21 billion gain from the spin off of its consumer health
Johnson & Johnson earnings: What to expect
03:13am, Tuesday, 17'th Oct 2023
Earnings: Analysts tracked by FactSet expect J&J JNJ, +0.43% to post per-share earnings of $2.52, down from $2.55 in the year-earlier period.
Markets Pop on Bargain Hunting, Stronger Economy
08:18pm, Monday, 16'th Oct 2023
The small-cap Russell 2000, still under water over the past month, led the way higher today.
Empire State Less Bad than Expected; SCHW Mixed in Q3
12:02pm, Monday, 16'th Oct 2023
We've only seen four months in positive territory on Empire State manufacturing year to date, the highest being +10.8 in April.
Wall Street Waits for Big Earnings Results
12:02pm, Monday, 16'th Oct 2023
Wall Street Waits for Big Earnings Results.
Johnson & Johnson: A Conservative High-Yield Dividend Aristocrat Buy
07:05am, Monday, 16'th Oct 2023
Johnson & Johnson is a defensive pick with a renewed focus on its pharmaceutical and medtech segments. The recent selloff in the stock has brought its valuation down to undervalued levels. Johnson & J
Wall Street spent much of this year getting more tepid on third-quarter corporate profits, with expectations for subdued growth giving way to expectations for a slight decline.
Johnson & Johnson Stock: Is Now the Time to Sell?
09:00am, Saturday, 14'th Oct 2023
Until recently Johnson & Johnson (NYSE: JNJ ) stock was the most conservative investment you could make in the drugs space. It still is, but that's no longer a compliment.
3 Dividend Growth Stocks You Can Buy and Hold Forever
06:52am, Saturday, 14'th Oct 2023
AbbVie boasts a stellar dividend track record and a resilient business. Eli Lilly's dividend yield might be low, but there's a lot more to the story.
Johnson & Johnson's 3Q earnings in spotlight next week following Kenvue split
02:08pm, Friday, 13'th Oct 2023
Johnson & Johnson (NYSE:JNJ) is slated to report earnings before the market opens on Tuesday in what will be the company's first report since spinning off its consumer health division, Kenvue. For i
Beat the Market With These 7 Warren Buffett Stocks
02:41pm, Thursday, 12'th Oct 2023
While targeting Warren Buffett stocks – that is, the securities under the holdings of conglomerate Berkshire Hathaway (NYSE: BRK-B ) – might not seem particularly exciting, the Oracle of Omaha may
2 No-Brainer Dividend King Stocks to Buy Right Now
08:45am, Wednesday, 11'th Oct 2023
Stocks have turned volatile in response to rising bond yields. High-quality dividend stocks could be a great way to ride out this rough patch.
Earnings Preview: Johnson & Johnson (JNJ) Q3 Earnings Expected to Decline
11:16am, Tuesday, 10'th Oct 2023
Johnson & Johnson (JNJ) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
J&J (JNJ) Seeks EU Nod for Rybrevant for First-Line NSCLC
12:46pm, Monday, 09'th Oct 2023
J&J (JNJ) files an application in Europe seeking expanded approval for Rybrevant as a first-line combination treatment in patients with advanced or metastatic EGFR exon 20 insertion mutation-positive
